共 44 条
- [21] Lbl-034, a Highly Differentiated T-Cell Engaging Bispecific Antibody Targeting GPRC5D for the Treatment of Relapsed or Refractory Multiple MyelomaBLOOD, 2023, 142Wang, BaohuiHuang, XiaoSun, JianmingQin, YurongShang, HongyanLi, TingtingWu, GuojinChen, MinWang, HailinZhang, PengJiang, DuqingLiu, TongjunYe, MiCai, ShengliLai, ShoupengKang, XiaoqiangLing, Hong
- [22] BMS-986393 (CC-95266), a G protein-coupled receptor class C group 5 member D (GPRC5D)-targeted CAR T-cell therapy for relapsed/refractory multiple myeloma (RRMM): results from a phase 1 studyCLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S54 - S55Nadeem, OmarBerdeja, JesusHtut, MyoKocoglu, M. HakanGregory, TaraAnderson, LarryRossi, AdrianaEgan, DanielCosta, LucianoKelly, LisaZiyad, SafiyyahHu, HongxiangChen, YanpingKaeding, AllisonBurgess, MichaelBal, Susan
- [23] BMS-986393 (CC-95266), a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor ( CAR) T-Cell Therapy for Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from a Phase 1 StudyBLOOD, 2023, 142Bal, SusanHtut, MyoNadeem, OmarLarry, Anderson D., Jr.Kocoglu, HakanGregory, TaraRossi, Adriana C.Martin, TomEgan, Daniel N.Costa, LucianoHu, HongxiangChen, YanpingLi, ShaoyiKelly, Lisa M.Sarkis, NaomeyZiyad, SafiyyahKao, Wei-MingKaeding, Allison JuneBurgess, Michael R.Berdeja, Jesus G.
- [24] G Protein-Coupled Receptor Class C Group 5 Member D (Gprc5d) and B-Cell Maturation Antigen (BCMA) Bi-Specific Dual Chimeric Antigen Receptors (CARS) Effectively Address Antigen Escape and Tumor Heterogeneity Challenge in Multiple Myeloma (MM)MOLECULAR THERAPY, 2024, 32 (04) : 205 - 206Chang, Chia-WeiDing, HuiWlodarek, LukaszNguyen, KevinLuo, YonghuaKarimi, MandanaRao, Shailaja P.Pal, Arpita S.Lai, Yi-shinGuan, SihuiLi, WeiminLan, Weijie
- [25] RG6234: A Novel 2:1 GPRC5D T Cell Bispecific Antibody Exhibits Best in Class Potential for the Treatment of Multiple Myeloma As a Monotherapy and in CombinationBLOOD, 2022, 140 : 2091 - 2092Eckmann, JanFauti, TanjaZabaleta, AintzaneBlanco, LauraKassem, SaharCarrie, NadegeLorenz, StefanCarpy, AlejandroChristopeit, TonyFertig, GeorgBernasconi, LuiseBiehl, MarleneDiggelmann, SarahKnobloch, MelanieMayoux, MaudDumontet, CharlesPaiva, BrunoMartinet, LudovicLeclair, StephaneXu, WeiKlein, ChristianUmana, Pablo
- [26] Clinical Activity of BMS-986393 (CC-95266), a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients with Relapsed and/or Refractory (R/R) Multiple Myeloma (MM): First Results from a Phase 1, Multicenter, Open-Label StudyBLOOD, 2022, 140Bal, SusanKocoglu, M. HakanNadeem, OmarHtut, MyoGregory, TaraAnderson, Larry D., Jr.Costa, Luciano J.Buchholz, Tonia J.Ziyad, SafiyyahLi, MengChen, YanpingKaeding, Allison J.Burgess, Michael R.Hege, KristenBerdeja, Jesus
- [27] Development of a quantitative systems pharmacology model for clinical dose and schedule optimization of RG6234, a T-cell engaging antibody targeting GPRC5D in multiple myelomaCANCER RESEARCH, 2023, 83 (07)Santini, Cristina C.Schindler, EmilieAttig, JanEckmann, JanVatakuti, SureshBrizzi, FrancescoSoubret, AntoineBelli, Sara
- [28] Forimtamig, a novel GPRC5D-targeting T-cell bispecific antibody with a 2+1 format, for the treatment of multiple myelomaBLOOD, 2025, 145 (02) : 202 - 219Eckmann, JanFauti, TanjaBiehl, MarleneZabaleta, AintzaneBlanco, LauraLelios, IvaGottwald, StefanRae, RichardLechner, StefanieBayer, ChristaDekempe, QuincyOsl, FranzCarrie, NadegeKassem, SaharLorenz, StefanChristopeit, TonyCarpy, AlejandroBujotzek, AlexanderBroeske, Ann-MarieDekhtiarenko, IrynaAttig, JanKunz, LeoCremasco, FlorianaAdelfio, RobertoFertig, GeorgDengl, StefanGassner, ChristianBormann, FelixKirstenpfad, ClaudiaKraft, ThomasDiggelmann, SarahKnobloch, MelanieHage, CarinaFeddersen, RomiHeidkamp, GordonPoeschinger, ThomasMayoux, MaudBernasconi, LuiseProsper, FelipeDumontet, CharlesMartinet, LudovicLeclair, StephaneXu, WeiPaiva, BrunoKlein, ChristianUmana, Pablo
- [29] Characterization and management of oral and dermatological toxicities in patients receiving the CD3 X GPRC5D bispecific antibody talquetamab for the treatment of relapsed/refractory multiple myelomaCLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S195 - S195Aronson, ElizabethPurcell, KiahAponte, AnnelLouw, KarenCatamero, DonnaLamb, AngelaKirke, DianaLucas, AimeeJagannath, SundarChari, Ajai